Filing Details

Accession Number:
0000899243-23-002075
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-18 17:58:22
Reporting Period:
2023-01-13
Accepted Time:
2023-01-18 17:58:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590750 Viridian Therapeutics Inc. VRDN Services-Medical Laboratories (8071) 471187261
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1841628 Barrett Katz C/O Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham MA 02453
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-13 4,147 $23.03 4,147 No 4 M Direct
Common Stock Disposition 2023-01-13 4,147 $37.01 0 No 4 S Direct
Common Stock Acquisiton 2023-01-17 24,853 $23.03 24,853 No 4 M Direct
Common Stock Disposition 2023-01-17 24,853 $37.21 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-01-13 4,147 $0.00 4,147 $23.03
Common Stock Stock Option (Right to Buy) Disposition 2023-01-17 24,853 $0.00 24,853 $23.03
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
291,853 2031-01-17 No 4 M Direct
267,000 2031-01-17 No 4 M Direct
Footnotes
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.